lorigerlimab
A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.
| Synonym: | anti-PD-1/anti-CTLA4 DART protein MGD019 bispecific DART protein MGD019 D-1 x CTLA4 DART protein MGD019 dual-affinity retargeting protein MGD019 PD-1 x CTLA4 bispecific DART molecule MGD019 PD-1 x CTLA4 DART protein MGD019 PD-1 x CTLA4 DART protein MGD019 |
|---|---|
| Code name: | AEX-1344 AEX1344 MGD 019 MGD-019 MGD019 |